Cytotoxicity and anti-HIV evaluations of some new synthesized quinazoline and thioxopyrimidine derivatives using 4-(thiophen-2-yl)-3,4,5,6-tetrahydrobenzo[h]quinazoline-2(1H)-thione as synthon

YAHIA A MOHAMED^a, ABD EL-GALIL E AMR^{b,c,*}, SALWA F MOHAMED^c, MOHAMED M ABDALLA^d, MOHAMED A AL-OMAR^e and SAMIRA H SHFIK^c

^aChemistry Department, Faculty of Science, El-Azhar University, Cairo 11787, Egypt

^bDrug Exploration and Development Chair (DEDC), College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia

^cApplied Organic Chemistry Department, National Research Centre, Dokki, Cairo 12622, Egypt

^dResearch Unit, Saco Pharm. Co., 6th October City, Cairo 15324, Egypt

^ePharmaceutical Chemistry Department, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia

e-mail: aamr1963@yahoo.com

MS received 24 April 2011; revised 14 September 2011; accepted 22 November 2011

Abstract. A series of dihydrobenzo[h]quinazoline derivatives **5–19** were synthesized using arylmethylene **2**, thiopyrimidine **3** and 2-(4-(thiophen-2-yl)-5,6-dihydrobenzo[h]quinazolin-2-ylthio) acetic acid (**4**) as a starting materials. The biological screening showed that many of these compounds have good anticancer and antiviral activities. The structure assignments of the new compounds based on chemical and spectroscopic evidence. The detailed synthesis, spectroscopic data, and pharmacological properties are reported.

Keywords. Arylmethylene; thiopyrimidine; dihydrobenzo[h]quinazolin-2-ylthioacetic acid; anticancer; antiviral and cytotoxic evaluations.

1. Introduction

The pyrimidinoyl and thioxopyrimidinoyl groups are of great importance in treating biological system. Analgesic, anti-arrhythmic, anticancer, antipyretic and anti-inflammatory activities are observed in some pyrimidinoyl and thioxopyrimidinoyl derivatives.^{1–5} Also, in our previous work we prepared certain new substituted heterocyclic derivatives which exhibit analgesic, anti-inflammatory, antiparkinsonian, and androgenic-anabolic activities.^{6–11} In addition, the heterocyclic nitrogen derivatives exhibited a general ionophoric potency for divalent cations¹² and used a novel thiocyanate-selective membrane sensor.¹³ Recently, anticancer and biological screening for some of synthesized heterocyclic compounds was reported.^{14–19} In view of these observations and in continuation of our previous work in heterocyclic chemistry, we have synthesized here of some new

derivatives containing quinazoline moiety. Some of the synthesized compounds were screened for their anticancer and antiviral activities due to structure similarity between our newly synthesized compounds and a clinically used agents in these fields.

2. Experimental

2.1 Chemistry

Melting points were determined on open glass capillaries using an Electrothermal IA 9000 digital melting point apparatus. Elemental analyses were performed on Elementar, Vario EL, Microanalytical Unit, National Research Center, Cairo, Egypt and were found within $\pm 0.4\%$ of the theoretical values. Infrared spectra were recorded on Carlzeise Spectrophotometer model “UR 10” spectrophotometer using the KBr disc technique. ¹H-NMR spectra were recorded on Varian Gemini 270 MHz spectrometer (DMSO-d₆) and the chemical shifts are given in δ (ppm) downfield from tetramethylsilane (TMS) as an internal standard. The mass spectra

*For correspondence

were measured using a Finnigan SSQ 7000 mass spectrometer. Follow up of the reactions and checking the purity of the compounds was made by TLC on silica gel-aluminum sheets (Type 60 F₂₅₄, Merck, Darmstadt, Germany).

2.1a 4-(Thiophen-2-yl)-5,6-dihydrobenzo[h]quinazolin-2-amine (5): To a boiling solution of compound **2** (2.4 g, 0.01 mol) in ethanolic potassium hydroxide (100 ml, 1%), guanidine hydrochloride (0.95 g, 0.01 mol) was added. The reaction mixture was refluxed for 5 h, then allowed to cool and the solid formed was filtered off, dried and crystallized to give compound **5** in yield: 83%; m.p: 220°C (EtOH); IR (KBr) $\nu_{\max}$: 3314, 3209 cm⁻¹ (NH₂). The IR spectrum is also devoid of the band corresponding to ν (C=O) present in the IR spectrum of **2**. ¹H NMR (270 MHz, DMSO-*d*₆): δ 2.84, 2.97 (2t, 4H, 2CH₂ of quinazoline ring), 6.56 (s, 2H, NH₂, D₂O exchangeable) 7.17–7.75 (m, 6H, Ar-H + thiophene-H), 8.12 (d, 1H, C₅-thiophene). MS *m/z* (%): 281 (M⁺+2, 100) corresponding to the molecular formula C₁₆H₁₃N₃S. Analysis: Calcd. C, 68.79; H, 4.69; N, 15.04; S, 11.48. Found C, 68.74; H, 4.65; N, 14.98; S, 11.43.

2.1b 4,5,6,7-Tetrachloro-2-(4-thiophen-2-yl-3,4,5,6-tetrahydro-benzo[h]quinazolin-2-yl)-isoindole-1,3-dione (6): A mixture of **5** (2.79 g, 0.01 mol) and 3,4,5,6-tetrachlorophthalic anhydride (2.85 g, 0.01 mol) was heated under fusion condition for 0.5 h., left to cool. The residue was triturated with ethanol and the obtained solid was filtered off, dried and crystallized to give compound **6** in yield: 61%; m.p: 252°C (AcOH); IR (KBr) $\nu_{\max}$: 1737 cm⁻¹ corresponding to ν (C=O). ¹H NMR (270 MHz, DMSO-*d*₆): δ 3.00–3.10 (m, 4H, 2CH₂ of quinazoline), 7.30–8.20 (m, 11H, Ar-H + thiophene-H). MS *m/z* (%): 547 (M⁺, 27) corresponding to the molecular formula C₂₄H₁₁Cl₄N₃O₂S and base peak at *m/z* 546 (100); Analysis: Calcd. C, 52.67; H, 2.03; Cl, 25.91; N, 7.68; S, 5.86. Found C, 52.61; H, 1.95; Cl, 25.86; N, 7.61; S, 5.78.

2.1c N-(4-(Thiophen-2-yl)-5,6-dihydrobenzo[h]quinazolin-2-yl)acetamide (7): A solution of **5** (2.79 g, 0.01 mol) in acetic anhydride (10 ml) was heated refluxed for 2 h. After cooling, the reaction mixture was poured onto ice water. The separated solid was collected by filtration, washed with water, dried and crystallized to give compound **7**, in yield: 72%; mp: 115°C (EtOH); IR (KBr) $\nu_{\max}$: 3207 and 1661 cm⁻¹ corresponding to ν (NH) and ν (C=O), respectively. ¹H

NMR (270 MHz, DMSO-*d*₆): δ 1.91 (s, 3H, CH₃), 2.94, 3.18 (2t, 4H, 2CH₂ of quinazoline ring), 7.27–8.10 (m, 7H, Ar-H + thiophene-H), 10.38 (s, 1H, NH, D₂O exchangeable). MS *m/z* (%): 321 (M⁺, 100); Analysis for C₁₈H₁₅N₃OS: Calcd. C, 67.27; H, 4.70; N, 13.07; S, 9.98. Found C, 67.23; H, 4.65; N, 13.03; S, 9.92.

2.1d N-(4-(Thiophen-2-yl)-5,6-dihydrobenzo[h]quinazolin-2-yl)methanesulphonamide (8): A mixture of compound **5** (2.79 g, 0.01 mol) and methylsulphonylchloride (1.14 g, 0.01 mol) in dry pyridine (20 ml) was heated at 70–75°C on a waterbath for 4 h. After cooling, the reaction mixture was acidified with diluted hydrochloric acid and the obtained solid was filtered off, washed with hot water, dried and crystallized to give compound **8** in yield: 67%; mp: 145°C (EtOH); IR (KBr) $\nu_{\max}$: 3344 cm⁻¹ corresponding to ν (NH). ¹H NMR (270 MHz, DMSO-*d*₆): δ 2.94–3.13 (2t, 4H, 2CH₂ of quinazoline ring), 3.57 (s, 3H, CH₃), 7.27–7.84 (m, 6H, Ar-H + thiophene), 8.15 (d, 1H, C₅ thiophene), 11.18 (s, 1H, NH, D₂O exchangeable). MS *m/z* (%): 357 (M⁺, 100) corresponding the molecular formula C₁₇H₁₅N₃O₂S₂; Analysis: Calcd. C, 57.12; H, 4.23; N, 11.76; S, 17.94. Found C, 57.06; H, 4.15; N, 11.70; S, 17.88.

2.1e 4-(Thiophen-2-yl)-5,6-dihydrobenzo[h]quinazoline-2(1H)-thione (9): A mixture of compound **3** (2.98 g, 0.01 mol) and sodium hydride (0.8 g, 0.02 mol) in dimethylformamide (40 ml) was stirred at 70–80°C for 1 h. then cooled to room temperature, chlorodiethyl ether (1 g, 0.01 mol) was added and heated at 90°C for 5 h. The reaction mixture was evaporated under reduced pressure, the obtained residue was triturated with water and the obtained solid was filtered off, dried and crystallized to give compound **9** in yield: 72%; m.p: 220°C (EtOH); IR (KBr) $\nu_{\max}$: 3416 (NH), 1189 cm⁻¹ (C=S); ¹H NMR (270 MHz, DMSO-*d*₆): δ 2.70, 3.20 (2t, 4H, 2CH₂ of quinazoline), 7.00–8.10 (m, 7H, Ar-H + thiophene), 8.54 (s, 1H, NH, D₂O exchangeable). MS *m/z* (%): 296 (M⁺, 95) corresponding the molecular formula C₁₆H₁₂N₂S₂ and base peak at 238 (100); Analysis: Calcd. C, 64.83; H, 4.08; N, 9.45; S, 21.64. Found C, 64.76; H, 4.03; N, 9.39; S, 21.58.

2.1f 1-(4-(Thiophen-2-yl)-2-thioxo-1,2,5,6-tetrahydro-benzo[h]quinazolin-3(4H)-yl)ethanone (11): A mixture of compound **3** (2.98 g, 0.01 mol), acetylchloride (0.78 g, 0.01 mol) in pyridine (30 ml) was refluxed for 2 h. The reaction mixture was poured onto acidified water (pH ~ 3), the solid formed was filtered off,

washed with water, dried and crystallized to give compound **11** in yield: 60%; m.p: 195°C (AcOH); IR (KBr) $\nu_{\max}$: 3257 and 1671 cm^{-1} corresponding to $\nu(\text{NH})$ and $\nu(\text{C}=\text{O}$, acetyl), respectively. ^1H NMR (270 MHz, DMSO- d_6): δ 2.30–2.90 (m, 7H, 2CH₂ + CH₃), 6.10 (s, 1H, CH of pyrimidine proton), 7.00–7.70 (m, 7H, Ar-H + thiophene-H), 11.80 (s, 1H, NH, D₂O exchangeable). MS m/z (%): 340 (M^+ , 10) corresponding the molecular formula C₁₈H₁₆N₂OS₂ and base peak at 297 (100); Analysis: Calcd. C, 63.50; H, 4.74; N, 8.23; S, 18.84. Found C, 63.46; H, 4.69; N, 8.17; S, 18.68.

2.1g S-[4-(Thiophen-2-yl)-3,4,5,6-tetrahydrobenzo[h]quinazolin-2-yl]-2-chloroethanethioate (12): A mixture of **3** (2.98 g, 0.01 mol) and chloroacetylchloride (1.12 g, 0.01 mol) in dry acetone (50 ml) in the presence of anhydrous K₂CO₃ (2.76 g, 0.02 mol) was refluxed on a waterbath for 24 h. The reaction mixture was evaporated under reduced pressure and the residue was triturated with water. The separated solid was filtered off, washed with water, dried and crystallized to give compound **12** in yield: 71%; m.p: 175°C (MeOH); IR (KBr) $\nu_{\max}$: 1721 cm^{-1} corresponding to $\nu(\text{C}=\text{O})$. IR spectrum taken as representative was devoid of bands corresponding to $\nu(\text{NH})$ and $\nu(\text{C}=\text{S})$ present in spectrum of the parent compound **3**. ^1H NMR (270 MHz, DMSO- d_6): δ 1.90, 2.70 (2t, 4H, 2CH₂ of quinazoline ring), 4.10 (s, 2H, CH₂), 6.00 (s, 1H, CH of pyrimidine proton), 6.90–7.80 (m, 7 H, Ar-H + thiophene-H) and 12.00 (s, 1H, NH, D₂O exchangeable). MS m/z (%): 374 (M^+ , 15) corresponding the molecular formula C₁₈H₁₅ClN₂OS₂ and base peak at 372 (100); Analysis: Calcd. C, 57.67; H, 4.05; Cl, 9.46; N, 7.47; S, 17.11. Found C, 57.63; H, 3.98; Cl, 9.41; N, 7.43; S, 17.06.

2.1h 2-(Methylthio)-4-(thiophen-2-yl)-5,6-dihydrobenzo[h]quinazoline (13): A mixture of compound **3** (2.98 g, 0.01 mol) and iodomethane (1.41 g, 0.01 mol) in ethanolic solution of sodium ethoxide (prepared from sodium metal 0.23 g, 10 mg-atom) in 20 ml ethanol was heated under reflux for 2 h. After acidification with acetic acid, the formed solid was collected by filtration and crystallized to give compound **13** in yield: 66%; m.p: 125°C (MeOH); IR (KBr) $\nu_{\max}$: 1592 cm^{-1} corresponding to $\nu(\text{C}=\text{N})$. The spectrum is also devoid of the bands corresponding to $\nu(\text{NH})$ and $\nu(\text{C}=\text{S})$ present in the IR spectrum of **3**. ^1H NMR (270 MHz, CDCl₃): δ 2.60 (s, 3H, SCH₃), 2.94, 3.19 (2t, 4H, 2CH₂ of quinazoline ring) and 7.10–8.30 (m, 6H, Ar-H + thiophene-H), 8.38 (d, 1H, C₅ thiophene). MS m/z (%): 310 (M^+ , 100, base peak) corresponding to the molecular formula C₁₇H₁₄N₂S₂. Analysis: Calcd. C, 65.77;

H, 4.55; N, 9.02; S, 20.66. Found C, 65.73; H, 4.50; N, 8.96; S, 20.61.

2.1i Ethyl 2-(4-(thiophen-2-yl)-5,6-dihydrobenzo[h]quinazolin-2-ylthio)acetate (14): A solution of compound **4** (3.54 g; 0.01 mol) in ethanol (50 ml) containing few drops of sulphuric acid was refluxed for 4 h, left to cool. The separated solid was filtered off, washed with water, dried and crystallized to give compound **14** in yield: 73%; m.p: 92°C (EtOH); IR (KBr) $\nu_{\max}$: 1744 cm^{-1} corresponding to $\nu(\text{C}=\text{O}$, ester). ^1H NMR (270 MHz, CDCl₃): δ 1.27 (t, 3H, CH₃), 2.93, 3.18 (2t, 4H, 2CH₂ of quinazoline ring), 4.00 (s, 2H, CH₂), 4.16 (q, 2H, CH₂), 6.00 (s, 1H, CH-pyrimidine), 7.15 (t, 1H, Ar-H), 7.25 (t, 1H, Ar-H), 7.37 (m, 2H, Ar-H), 7.56 (m, 2H, Ar-H), 8.30 (d, 1H, C₅-thiophene). MS m/z (%) 382 (M^+ , 25) corresponding the molecular formula C₂₀H₁₈N₂O₂S₂ and base peak at 309 (100). Analysis: Calcd. C, 62.80; H, 4.74; N, 7.32; S, 16.77. Found C, 62.74; H, 4.69; N, 7.27; S, 16.72.

2.1j 2-(4-(Thiophen-2-yl)-5,6-dihydrobenzo[h]quinazolin-2-ylthio)acetohydrazide (15): A mixture of **14** (3.82 g, 0.01 mol) and hydrazine hydrate (3.1 ml 80%, 0.05 mol) in absolute ethanol (20 ml) was stirred for 6 h. The obtained solid was filtered off and crystallized to give compound **15** in yield: 69%; m.p: 180°C (EtOH); IR (KBr) $\nu_{\max}$: 3269, 3154 cm^{-1} (NH, NH₂), 1653 cm^{-1} (C=O). ^1H NMR (270 MHz, DMSO- d_6): δ 2.93, 3.16 (2t, 4H, 2CH₂ of quinazoline ring), 3.91 (s, 2H, CH₂), 4.26 (s, 2H, NH₂, D₂O exchangeable), 7.26–7.87 (m, 6H, Ar-H + thiophene-H), 8.20 (d, 1H, C₅-thiophene) 9.31 (s, 1H, NH, D₂O exchangeable). MS m/z (%): 368 (M^+ , 30) corresponding to the molecular formula C₁₈H₁₆N₄OS₂ with base peak at 309. Analysis: Calcd. C, 58.67; H, 4.38; N, 15.21; S, 17.40. Found C, 58.61; H, 4.32; N, 15.15; S, 17.32.

2.1k Synthesis of compounds (16) and (17): A mixture of compound **15** (3.7 g, 0.01 mol) and phthalic anhydride or 3,4,5,6-tetrachlorophthalic anhydride (0.01 mol) in glacial acetic acid (50 ml) was heated under reflux for 6 h. The reaction mixture was evaporated under reduced pressure; the obtained residue was solidified with ether, filtered off, and crystallized from the proper solvent to give **16** and **17**, respectively.

2.1l N-(1,3-Dioxoisindolin-2-yl)-2-(4-(thiophen-2-yl)-5,6-dihydrobenzo[h]quinazolin-2-ylthio)-acetamide (16): Yield 74%; mp. 190°C (AcOH/H₂O); IR (KBr) $\nu_{\max}$: IR spectrum of compound **16** demonstrated the

presence of the bands at: 3268 cm^{-1} corresponding to $\nu(\text{NH})$, 1752 , 1672 cm^{-1} corresponding to $\nu(\text{C}=\text{O})$. ^1H NMR (270 MHz, DMSO- d_6): δ 2.90–3.20 (m, 4H, 2CH_2 of quinazoline ring), 4.01 (s, 2H, CH_2), 7.23–8.40 (m, 11H, Ar-H + thiophene-H) 9.85 (s, 1H, NH). MS m/z (%): 495 ($\text{M}^+ - 3$; 1) corresponding to molecular formula $\text{C}_{26}\text{H}_{18}\text{N}_4\text{O}_3\text{S}_2$, a base peaks at m/z 309 (100). Analysis: Calcd. C, 62.63; H, 3.64; N, 11.24; S, 12.86. Found: C, 62.57; H, 3.57; N, 11.18; S, 12.80.

2.1m *N*-(4,5,6,7-tetrachloro-1,3-dioxoisindolin-2-yl)-2-(4-(thiophen-2-yl)-5,6-dihydrobenzo[h]-quinazolin-2-ylthio)acetamide **17**: Yield 78%; mp. 150°C (AcOH/H $_2\text{O}$); IR (KBr) ν_{max} : spectrum of compound **17** demonstrated the presence of the bands at: 3168 cm^{-1} corresponding to $\nu(\text{NH})$, 1747, 1713 cm^{-1} corresponding to $\nu(\text{C}=\text{O})$. MS m/z (%): 637 ($\text{M}^+ + 1$, 2), corresponding to molecular formula $\text{C}_{26}\text{H}_{14}\text{Cl}_4\text{N}_4\text{O}_3\text{S}_2$ with base peak at: m/z 214 (100). Analysis: Calcd.: C, 49.07; H, 2.22; N, 8.80; S, 10.08. Found: C, 49.01; H, 2.16; N, 8.74; S, 10.01.

2.1n *Synthesis of compounds (18) and (19)*: A mixture of the acid hydrazide **15** (3.82 g, 0.01 mol) and phenylisothiocyanate or *p*-fluorobenzaldehyde (0.01 mol) in absolute ethanol (50 ml) was refluxed for 3–7 h. After cooling, the separated solid was filtered off and crystallized from the proper solvent to afford the corresponding compounds **18** and **19**, respectively.

2.1o *N*-phenyl-2-(2-(4-(thiophen-2-yl)-5,6-dihydrobenzo[h]quinazolin-2-ylthio)acetyl)hydrazin-0-carbothioamide **18**: Yield 60%; mp. 195°C (EtOH); IR (KBr) ν_{max} : spectrum of compound **18** showed absorption bands at 3347 , 3266 cm^{-1} corresponding to $\nu(\text{NH})$, 1680 cm^{-1} corresponding to $\nu(\text{C}=\text{O})$. ^1H NMR (270 MHz, DMSO- d_6): δ 2.90, 3.12 (2t, 4H, 2CH_2 quinazoline), 4.09 (s, 2H, CH_2), 7.23–7.85 (m, 10 H, Ar-H + thiophene-H) 8.28(d, 1H, C_5 thiophene) 9.29, 9.66 and 10.32 (3s, 3H, 3NH). Analysis for $\text{C}_{25}\text{H}_{21}\text{N}_5\text{OS}_3$ (503.66): Calcd.: C, 59.62; H, 4.20; N, 13.09; S, 19.10. Found: C, 59.55; H, 4.15; N, 13.04; S, 19.05.

2.1p *N'*-(4-fluorobenzylidene)-2-(4-(thiophen-2-yl)-5,6-dihydrobenzo[h]quinazolin-2-ylthio)aceto-hydrazide **19**: Yield 62%; mp. 225°C (EtOH); IR (KBr) ν_{max} : spectrum of compound **19** showed absorption bands at: 3247 , 1662 cm^{-1} corresponding to $\nu(\text{NH})$ and (C=O), respectively. ^1H NMR (270 MHz, DMSO- d_6): δ 2.82, 3.00 (2t, 4H, 2CH_2 of quinazoline), 4.01 (s,

2H, CH_2), 7.24–8.25 (m, 12H, Ar-H + thiophene-H + $\text{CH}=\text{N}$), 11.62 (1s, 1H, NH). Analysis for $\text{C}_{25}\text{H}_{19}\text{FN}_4\text{OS}_2$ (474.57): Calcd.: C, 63.27; H, 4.04; N, 11.81; S, 13.51. Found: C, 63.21; H, 3.97; N, 11.74; S, 13.47.

2.2 Biological screening in vitro cytotoxicity

The cytotoxicity of the newly synthesized compounds against cancer cell lines *in vitro* was performed with the MTT assay according to the Mosmann's method.²⁰ The MTT assay is based on the reduction of the soluble 3-(4,5-methyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) into a blue-purple formazan product, mainly by mitochondrial reductase activity inside living cells. The cells used in cytotoxicity assay were cultured in RPMI 1640 medium supplemented with 10% fetal calf serum. Cells suspended in the medium ($2 \times 10^4/\text{mL}$) were plated in 96-well culture plates and incubated at 37°C in a 5% CO_2 incubator. After 12 h, the test sample (2 μL) was added to the cells (2×10^4) in 96-well plates and cultured at 37°C for 3 days.

The cultured cells were mixed with 20 μL of MTT solution and incubated for 4 h at 37°C . The supernatant was carefully removed from each well and 100 μL of DMSO were added to each well to dissolve the formazan crystals which were formed by the cellular reduction of MTT. After mixing with a mechanical plate mixer, the absorbance of each well was measured by a microplate reader using a test wavelength of 570 nm. The results were expressed as the IC_{50} , which inducing a 50% inhibition of cell growth of treated cells when compared to the growth of control cells. Each experiment was performed at least 3 times. There was a good reproducibility between replicate wells with standard errors below 10%.

2.2a HIV inhibitor activities (reverse transcriptase inhibitors) with therapeutic windows (cells and viruses): The established human cells, laboratory-derived virus isolates (including drug-resistant virus isolates), and low-passage clinical virus isolates used in these evaluations have previously been described in detail.²¹ These cells were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum, 2 mM glutamine, penicillin (100 U/ml), and streptomycin (100 $\mu\text{g}/\text{ml}$). Fresh human cells were obtained from the American Red Cross (Baltimore, Md.).

2.2b Antiviral and cross-resistance assays: The inhibitory activities of the compounds against HIV were

evaluated by microtiter anti-HIV assays with CEM-SS cells or fresh human peripheral blood mononuclear cells (PBMCs); these assays quantify the ability of a compound to inhibit HIV-induced cell killing or HIV replication. Quantification was performed by the tetrazolium dye XTT assay (CEM-SS, 174×CEM, MT2, and AA5 cell-based assays), which is metabolized to a coloured formazan product by viable cells, RT assay (U937- and PBMC-based assays), and/or p24 enzyme-linked immunosorbent assay (monocyte-macrophage assays). Antiviral and toxicity data are reported as the quantity of drug required for inhibiting virus-induced cell killing or virus production by 50% (EC₅₀).

2.2c *In vitro* assays of anti-HIV activity: Purified RT assays of the newly synthesized compounds were tested for RT inhibitory activity against purified recombinant HIV-1 RT using the cell-free Quan-T-RT assay system (Amersham Corp., Arlington Heights, IL), which utilizes the scintillation proximity assay (SPA) principle, as described in detail.²²

In the assay, a DNA/RNA template is bound to SPA beads via a iotin/streptavidin linkage. The primer DNA is a 16-mer oligo(T), which has been annealed to a poly(rA) template. The primer-template is bound to a streptavidin-coated SPA bead. [³H]TTP (thymidine -5'- triphosphate) is incorporated into the primer by reverse transcription. In brief, [³H]TTP, at a final concentration of 0.5 µCi/sample, was diluted in RT assay buffer (49.5 mM Tris-HCl, pH 8.0, 80 mM KCl, 10 mM MgCl₂, 10 mM dithiothreitol, 2.5 mM EDTA, 0.05% Nonidet P-40) and added to annealed DNA/RNA bound to SPA beads. The compound being tested was added to the reaction mixture at 0.001–100 µM concentrations. Addition of 10 mU of recombinant HIV RT and incubation at 37°C for 1 h resulted in the extension of the primer by incorporation of [³H]TTP. The reaction was stopped by addition of 0.2 ml of 120 mM EDTA. The samples were counted in an open window using a Beckman LS 7600 instrument and IC_{50[RT]} values (concentration at which the compound inhibits recombinant RT by 50%) were calculated by comparing the measurements to an untreated.

2.2d *Hepatitis C virus (HCV) NS3-4A protease inhibitor activities:* The success of human immunodeficiency virus (HIV) protease inhibitors in treating HIV-infected patients has raised the hope that inhibitors of HCV NS3-4A serine protease could also become effective therapy options for hepatitis C patients.

Parental Huh-7 and HepG2 cells were cultured in Dulbecco's modified Eagle's medium (DMEM)

containing 10% heat-inactivated fetal bovine serum (FBS), 2 mM L-glutamine, and non-essential amino acids. Stable Huh-7 cells containing the self-replicating, sub-genomic HCV replicon, which was identical in sequence to the I377neo/NS3-3'/wt replicon described by Lohmann *et al.*²³ were selected and maintained in the presence of 0.25 mg/ml G418 (Invitrogen, Carlsbad, CA) and were used for anti-HCV assays. Peripheral blood mononuclear cells (PBMC) were isolated from fresh donor blood and cultured in RPMI-1640 medium (JRH Biosciences).

2.2e *Determination of anti-HCV activity and cytotoxicity:* Determination of 50% inhibitory concentration (IC₅₀), 90% inhibitory concentration (IC₉₀), and 50% cytotoxic concentration (CC₅₀) of all the tested compounds in HCV replicon cells was performed as described. Pre-clinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus (NS3-4A serine protease). Briefly, 1 × 10⁴ replicon cells per well were plated in 96-well plates. On the following day, replicon cells were incubated at 37°C for the indicated period of time with antiviral agents serially diluted in DMEM plus 2% FBS and 0.5% dimethylsulphoxide (DMSO). Total cellular RNA was extracted using an RNeasy-96 kit (QIAGEN, Valencia, CA), and the copy number of HCV RNA was determined using a quantitative RT-PCR (QRT-PCR) assay. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells. Each datum point represents the average of five replicates in cell culture. The cytotoxicity of the tested compounds was measured under the same experimental settings using a tetrazolium (MTS)-based cell viability assay. For the cytotoxicity assay with human hepatocyte cell lines, 1 × 10⁴ parental Huh-7 cells per well or 4 × 10⁴ HepG2 cells per well were used. To determine cytotoxicity of the tested compound against resting PBMC, 1 × 10⁵ cells per well were incubated with the tested compound in RPMI-1640 medium (no serum) for 48 h, and the cell viability was determined by the MTS-based assay. To determine cytotoxicity of the tested compound against proliferating PBMC, 1 × 10⁵ cells per well in RPMI-1640 medium were added to a 96-well plate, which was pre-coated with anti-human CD3 antibody (Accurate Chemical and Scientific Corporation, Westbury, NY). The cells were incubated with the tested compound and anti-human CD28 antibody (Pharmingen/BD Biosciences, San Jose, CA) for 72 h at 37°C, and the cell growth was determined by [³H]thymidine uptake between the 48th and 72nd h.

Scheme 1.

3. Results and discussion

3.1 Chemistry

In our previous work,⁶⁻¹⁹ we reported the synthesis and a preliminary biological activity screening of several thiopyrimidine derivatives based on arylmethylene **2**, 4-thiophen-2-yl-3,4,5,6-tetrahydro-1H-benzo[h]quinazoline-2-thione (**3**) and 2-(4-(thiophen-2-yl)-5,6-dihydrobenzo[h]quinazolin-2-ylthio) acetic acid (**4**), which were synthesized according to the literature procedures²⁴ (scheme 1).

Arylmethylene **2** was allowed to react with guanidine hydrochloride in ethanolic potassium hydroxide to yield the corresponding 4-thiophen-2-yl-5,6-dihydrobenzo[h]quinazolin-2-ylamine (**5**), which was reacted

with 3,4,5,6-tetrachlorophthalic anhydride under fusion to yield 4,5,6,7-tetrachloro-2-(4-thiophen-2-yl-3,4,5,6-tetrahydrobenzo[h]quinazolin-2-yl)isoindole-1,3-dione (**6**). Also, amino-pyrimidine **5** was treated with acetic anhydride or methyl sulphonylchloride to afford the corresponding N-(4-thiophen-2-yl-5,6-dihydrobenzo[h]quinazolin-2-yl)-acetamide (**7**) and N-(4-thiophen-2-yl-5,6-dihydrobenzo[h]quinazolin-2-yl)methanesulphonamide (**8**), respectively (scheme 2).

In addition, thioxopyrimidine **3** was reacted with chlorodiethyl ether in the presence of sodium hydride afforded 4-thiophen-2-yl-5,6-dihydro-1H-benzo[h]quinazoline-2-thione (**9**) rather than the S-alkylated form **10**. 2-Thiopyrimidine **3** underwent alkylation giving S-alkylation or N-alkylation depending on the reaction conditions. So, when compound **3** was refluxed in acetylchloride or chloro-acetylchloride afforded the corresponding 1-(4-thiophen-2-yl-2-thioxo-1,4,5,6-tetrahydro-2H-benzo[h]-quinazolin-3-yl)ethanone (**11**) and S-[4-(thiophen-2-yl)-3,4,5,6-tetrahydrobenzo[h]quinazolin-2-yl] 2-chloroethanethioate (**12**), respectively. On the other hand, compound **3** was reacted with methyl iodide to afford 2-methylsulfanyl-4-thiophen-2-yl-5,6-dihydrobenzo[h]quinazoline (**13**) (scheme 3).

On the other hand, When esterification of the carboxylic acid derivative **4** with refluxed ethanol in the presence of concentrated sulphuric acid afforded ethyl 2-(4-(thiophen-2-yl)-5,6-dihydrobenzo[h]quinazolin-2-ylthio)acetate (**14**), which was treated with hydrazine hydrate in ethanol to produce (4-thiophen-2-yl-3,4,5,

Scheme 2.

Scheme 3.

6-tetrahydrobenzo[h] quinazolin-2-ylsulfanyl)-acetohydrazide **15**. The reaction of the hydrazide **15** with phthalic anhydride or 3,4,5,6-tetrachlorophthalic anhydride in glacial acetic acid furnished pyrrolobenzene derivatives **16** and **17**, respectively. On the other hand, treatment of hydrazide **15** with phenyl isothiocyanate or *p*-florobenzaldehyde in ethanol under reflux afforded thiosemicarbazide **18** and hydrazone **19**, respectively (scheme 4).

3.2 Biological activity

Some of the newly synthesized compounds were tested for their cytotoxicity on different cancer cell lines and virus. The obtained results were summarized in the following tables 1–4.

3.2a Anticancer activity: Regarding the anticancer activity careful examining of the data obtained from table 1, compounds **2**, **3**, **4**, **6**, **9**, **11**, **12**, **13**, **14**, **15**, **16** and **19** showed potent cytotoxic activity against Leukemia (HL60, U937 and K562), melanoma (G361 and SK-MEL-28), neuroblast (GOTO and NB-1) and normal cell carcinoma (W138) cell lines. The most active compounds are **2**, **6**, **9**, **13**, **15** and **19**. It is worth to mention that most of the tested compounds showed potent activities where they have minimal IC_{50} . From table 2, the same compounds showed cytotoxic activity against cervical carcinoma (KB), CNS (SF-268), colon,

Scheme 4.

Table 1. The activities of the tested compounds on some cancer cell lines.

Product	IC ₅₀							
	Leukaemia			Melanoma		Neuroblast		Normal cell carcinoma
	HL60	U937	K562	G361	SK-MEL-28	GOTO	NB-1	W138
2	5.4	4.4	1.4	1.5	5.2	7.5	4.7	6.4
	E-03	E-03	E-03	E-03	E-03	E-03	E-03	E-03
3	3.5	6.4	6.4	6.8	7.9	9.7	9.7	9.7
	E-03	E-03	E-03	E-03	E-03	E-03	E-03	E-03
4	8.3	8.7	7.2	8.8	7.7	6.6	8.5	9.8
	E-03	E-03	E-03	E-03	E-03	E-03	E-03	E-03
6	8.9	9.0	8.7	7.9	9.8	8.7	4.3	-
	E-03	E-03	E-03	E-03	E-03	E-03	E-03	-
9	2.4	3.5	7.4	7.3	4.2	4.7	3.1	8.4
	E-03	E-03	E-03	E-03	E-03	E-03	E-03	E-03
11	6.4	6.4	5.7	9.7	6.5	4.5	8.5	6.8
	E-03	E-03	E-03	E-03	E-03	E-03	E-03	E-03
12	7.8	9.8	8.0	9.7	9.7	9.7	6.8	9.7
	E-03	E-03	E-03	E-03	E-03	E-03	E-03	E-03
13	8.8	8.9	7.0	7.8	8.0	7.6	3.2	8.7
	E-03	E-03	E-03	E-03	E-03	E-03	E-03	E-03
14	6.7	9.8	9.8	7.6	9.0	9.8	7.6	7.6
	E-03	E-03	E-03	E-03	E-03	E-03	E-03	E-03
15	6.4	7.7	7.9	4.0	2.8	9.2	8.7	1.4
	E-03	E-03	E-03	E-03	E-03	E-03	E-03	E-03
16	7.8	9.8	7.6	7.5	8.3	6.4	9.6	9.0
	E-03	E-03	E-03	E-03	E-03	E-03	E-03	E-03
19	5.3	5.3	3.5	3.5	5.1	3.2	6.8	7.9
	E-03	E-03	E-03	E-03	E-03	E-03	E-03	E-03

adenocarcinoma (RKOP27), ovarian carcinoma (SKOV-3) and non-small-cell lung cancer (NCI H-460) cancer cell lines. The most active compounds are **2**, **4** and **11**. Also the tested compounds showed potent activities where they have minimal IC₅₀.

3.2b Anti-HIV activity: Regarding the anti-HIV activities, compounds **2**, **3**, **4**, **6**, **9**, **11**, **12**, **13**, **14**, **15**, **16** and **19** showed potent anti-HIV activities and the descending order of the activity is **6**, **13**, **3**, **12**, **19**, **14**, **19**, **15**, **2**, **9**, **16**, **4** and **11** (table 3). Concerning the mechanism of action as anti-HIV, these compounds were reverse transcriptase inhibitors.

Table 2. Cytotoxicity of some new compounds on some new cancer cell lines.

Product	IC ₅₀				
	KB	SK OV-3	SF-268	NCI H460	RKOP27
2	4.9 E-03	5.9 E-03	3.0 E-03	2.4 E-03	3.3 E-03
3	5.6 E-03	5.4 E-03	6.7 E-03	7.6 E-03	9.8 E-03
4	3.9 E-03	4.7 E-03	5.8 E-03	5.9 E-03	5.0 E-03
6	9.0 E-03	9.0 E-03	6.0 E-03	9.6 E-03	9.5 E-03
9	6.5 E-03	9.8 E-03	9.4 E-03	4.9 E-03	6.5 E-03
11	3.0 E-03	4.0 E-03	4.0 E-03	4.8 E-03	4.9 E-03
12	7.8 E-03	9.8 E-03	7.6 E-03	6.6 E-03	8.7 E-03
13	8.8 E-03	6.9 E-03	5.0 E-03	6.0 E-03	6.0 E-03
14	7.8 E-03	5.4 E-03	5.4 E-03	6.7 E-03	9.0 E-03
15	4.3 E-03	9.8 E-03	5.6 E-03	7.6 E-03	9.8 E-03
16	7.8 E-03	9.4 E-03	7.8 E-03	6.7 E-03	9.0 E-03
19	4.9 E-03	9.8 E-03	7.6 E-03	6.5 E-03	8.7 E-03

Table 3. HIV inhibitor activities (reverse transcriptase inhibitors) with therapeutic windows.

Product	EC ₅₀ /Mm	IC ₅₀ /μM	Therapeutic index
2	0.00525	6.1	33000
3	0.00722	2.6	32122
4	0.00084	17.4	784,532
6	2.44×10^{-4}	2.11	1.89×10^5
9	0.00778	8.1	44432
11	5.44×10^{-4}	22.6	8.34×10^5
12	3.71×10^{-4}	2.9	3.66×10^5
13	6.24×10^{-5}	2.33	2.15×10^6
14	10^{-4}	4.4	2.33×10^5
15	0.00871	5.6	92160
16	2.3	16.2	40
19	0.00691	3.4	103654

Table 4. Hepatitis C virus (HCV) NS3-4A protease inhibitor activities.

Product	IC ₅₀ (±SD)μM after 48 h	IC ₉₀ (±SD)μM after 48 h	CC50 (±SD)μM	Window index
2	0.318 ± 0.042	2.78 ± 0.077	2738 ± 8.5	2201.450
4	0.188 ± 0.022	0.501 ± 0.033	516 ± 4.5	2723.450
11	0.288 ± 0.031	1.89 ± 0.066	1788 ± 6.5	2399.600
14	0.244 ± 0.035	0.897 ± 0.053	716 ± 6.8	2578.500
16	0.145 ± 0.020	0.301 ± 0.021	215 ± 3.2	2829.540

3.2c Anti-HCV activity: Regarding the anti-HCV activities, compounds **2**, **4**, **11**, **14**, and **16** showed potent anti-HCV activities and the descending order of the activity is **16**, **4**, **14**, **11** and **2** (table 4). Concerning the mechanism of action as anti-HCV, these compounds were HCV NS3-4A protease inhibitor activities.

3.3 Structure activity relationship (SAR)

- From tables 1 and 2, all the tested compounds showed activity against leukemia (HL60, U937 and K562), melanoma (G361 and SK-MEL-28), neuroblast (GOTO and NB-1), normal cell carcinoma (W138), cervical carcinoma (KB), CNS (SF-268), colon adenocarcinoma (RKOP27), ovarian carcinoma (SKOV-3) and non-small-cell lung cancer (NCI H-460) cancer cell lines. In addition, the presence of pyrimidine ring fused with tetrahydronaphthalene and carboxylic acid as substituted due to the increase the anticancer activity.
- From tables 3 and 4, regarding the anti-HIV and anti-HCV activities fusion of thiophene to the pyrimidine nucleus and attaching of opened chain nucleus to the central atom greatly intensify the activity.
- Compounds **2**, **4**, **6**, **11**, and **16** showed better activity compared to other derivatives due to their content of multi-basic centres able to facile hydrogen bonding with receptor sites and improve their planarity character that enable them to inter chelate with DNA and RNA.
- Compound **16** showed higher biological activity than **17**, may be due to the presence of chlorine atoms that deform the planarity of the molecule and hinder the interchelation with target receptor.

4. Conclusion

A series of dihydrobenzo[h]quinazoline derivatives **5–19** were synthesized using arylmethylene **2**, thiopyrimidine **3** and 2-(4-(thiophen-2-yl)-5,6-dihydrobenzo[h]quinazolin-2-ylthio) acetic acid (**4**) as

a starting materials. The biological screening showed that many of these compounds have good anticancer and antiviral activities.

Acknowledgements

The Authors thank the Deanship of Scientific Research at King Saud University for funding the work through the research group project No. RGP-VPP-099.

References

1. Zigeuner G, Lintschinger W B, Fuchsgruber A and Kollmann K 1976 *Monatsh. Chem.* **107** 171
2. Mathes R A and Stewart F D 1950 *J. Am. Chem. Soc.* **72** 1879
3. Moustafa H M, Khodairy A and El-Saghier A M M 2003 *Phosphorus Sulfur* **178** 1211
4. Bakhite E A, Abdel-Rahman A and Al-Taifi E A 2004 *Phosphorus Sulfur* **179** 513
5. Pathak U S, Devani M B, Shishoo C J, Kulkarni R R, Rakholia V M, Bhadti V S, Ananthan S, Dave M G and Shah V A 1986 *Indian J. Chem. B.* **25B** 489
6. Amr A E, Hegab M I, Ibrahim A A and Abdalah M M 2003 *Monatsh. Chem.* **134** 1395
7. Amr A E and Abdulla M M 2002 *Indian J. Heterocycl. Chem.* **12** 129
8. Nehad A A, Amr A E and Alhusien A I 2007 *Monatsh. Chem.* **138** 559
9. Amr A E, Nermien M S and Abdulla M M 2007 *Monatsh. Chem.* **138** 699
10. Amr A E, Ashraf M M, Salwa F M, Nagla A A and Hammam A G 2006 *Bioorg. Med. Chem.* **14** 5481
11. Amr A E, Sayed H H and Abdulla M M 2005 *Arch. Pharm. Chem. Life Sci.* **338** 433
12. Hassan S S M, Abou-Ghaila M H, Amr A E and Mohamed A H K 2003 *Talanta* **60** 81
13. Hassan S S M, Abou-Ghaila M H, Amr A E and Mohamed A H K 2003 *Anal. Chem. Acta.* **482** 9
14. Amr A E, Nehad A A and Abdalla M M 2006 *Bioorg. Med. Chem.* **14** 373
15. Amr A E and Abdalla M M 2006 *Bioorg. Med. Chem.* **14** 4341
16. Amr A E, Nermien M S, Abdalla M M and Bakr F A 2009 *Eur. J. Med. Chem.* **44** 725
17. Amr A E, Korany A A and Abdalla M M 2009 *Eur. J. Med. Chem.* **44** 901

18. Amr A E, Abo-Ghalia M H and Abdalla M M 2007 *Arch. Pharm. Chem. Life Sci.* **340** 304
19. Issa M F, Amr A E, Nermien M S and Abdalla M M 2008 *Arch. Pharm. Chem. Life Sci.* **341** 174
20. Jr Buckheit R W, Kinjerski T L, Fliakas-Boltz V, Russell J D, Stup T L, Pallansch L A, Brouwer W G, Dao D C, Harrison W A, Schultz R J, Bader J P and Yang S S 1995 *Antimicrob. Agents Chemother.* **39** 2718
21. Zarling J M, Moran P A, Haffar O, Diegel M, Myers D E, Kuelbeck V, Ledbetter J A and Uckun F M 1991 *Int. J. Immunopharmacol.* **13** 63
22. Lin K, Kwong A D and Lin C 2004 *Antimicrob. Agents Chemother* **48** 4784
23. Lohmann V, Korner F, Koch J, Herian U, Theilmann L and Bartenschlager R 1999 *Science* **285** 110
24. Mohamed S F, Thabet H Kh, Mustafa E E, Abdalla M M and Shafik S H 2009 *World J. Chem.* **4** 100